Pluri (DB:4DX) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

4DX Overzicht aandelen

A biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries.

Over het bedrijf

4DX fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

De winst is de afgelopen 5 jaar met 3.6% per jaar gegroeid

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $341K )

Aandelen zijn zeer illiquide

Heeft geen betekenisvolle marktkapitalisatie ( €27M )

Aandeelhouders zijn het afgelopen jaar verwaterd

Pluri Inc. Concurrenten

2invest

XTRA:2INV

€59.8m

Medigene

XTRA:MDG1

€27.6m

co.don

XTRA:CNW

€6.5m

Heidelberg Pharma

XTRA:HPHA

€124.4m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Pluri
Historische aandelenkoersen
Huidige aandelenkoers	US$5.60
52 Week Hoogtepunt	US$7.32
52 Week Laag	US$3.10
Bèta	1.62
11 maand verandering	0%
3 maanden verandering	-10.83%
1 Jaar Verandering	1.45%
33 jaar verandering	-79.24%
5 jaar verandering	-86.89%
Verandering sinds IPO	-76.74%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	4DX	DE Biotechs	DE Markt
7D	0%	0.7%	1.1%
1Y	1.4%	-8.5%	18.9%

Rendement versus industrie: 4DX overtrof de German Biotechs industrie, die het afgelopen jaar een rendement -15.1 % opleverde.

Rendement versus markt: 4DX presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 13.8 % opleverde.

Prijsvolatiliteit

Is 4DX's price volatile compared to industry and market?
4DX volatility
4DX Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van 4DX is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 4DX in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2001	129	Yaky Yanay	www.pluri-biotech.com

Pluri Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Pluri zich tot de beurswaarde?
4DX fundamentele statistieken
Marktkapitalisatie	€24.83m
Inkomsten(TTM)	-€20.13m
Inkomsten(TTM)	€317.54k

78.2x

P/S-verhouding

-1.2x

Koers/Winstverhouding

Is 4DX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
4DX resultatenrekening (TTM)
Inkomsten	US$341.00k
Kosten van inkomsten	US$9.00k
Brutowinst	US$332.00k
Overige uitgaven	US$21.95m
Inkomsten	-US$21.62m

Laatst gerapporteerde inkomsten

Mar 31, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-4.01
Brutomarge	97.36%
Nettowinstmarge	-6,339.59%
Schuld/Eigen Vermogen Verhouding	1,304.3%

Hoe presteerde 4DX op de lange termijn?

Bekijk historische prestaties en vergelijking

4DX Overzicht aandelen

Beloningen

Risicoanalyse

Pluri Inc. Concurrenten

XTRA:2INV

€59.8m

XTRA:MDG1

€27.6m

XTRA:CNW

€6.5m

XTRA:HPHA

€124.4m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Nasdaq Grants Extension Till Nov. 24 to Pluri Inc. to Regain Compliance with Stockholder Equity Requirement

Pluri Inc. Announces Executive Changes, Effective September 30, 2024

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri Inc.’s PLX-R18 Acute Radiation Syndrome Contract

Pluri Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Pluri Inc., Annual General Meeting, Jun 25, 2024

New minor risk - Shareholder dilution

Recent updates

Nasdaq Grants Extension Till Nov. 24 to Pluri Inc. to Regain Compliance with Stockholder Equity Requirement

Pluri Inc. Announces Executive Changes, Effective September 30, 2024

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri Inc.’s PLX-R18 Acute Radiation Syndrome Contract

Pluri Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Pluri Inc., Annual General Meeting, Jun 25, 2024

New minor risk - Shareholder dilution

Pluri Inc. Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

Pluri Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Second quarter 2024 earnings released: US$0.12 loss per share (vs US$0.24 loss in 2Q 2023)

Pluri Inc. Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis

Pluri Inc. Appoints Andy Lewin to Lead Business of its Contract Development and Manufacturing Organization: PluriCDMO Division

First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.19 loss in 1Q 2023)

Pluri Receives an Extension of an Additional 180 Calendar Days from The Nasdaq Stock Market LLC to Regain Compliance with the Minimum Bid Price Requirement

Full year 2023 earnings released: US$0.77 loss per share (vs US$1.28 loss in FY 2022)

Pluri Inc. Announces PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in Phase I Study: Results Published in Nature Bone Marrow Transplantation

Pluri Inc. Announces Appointment of Lorne Abony to Board of Directors

Pluri Inc. announced that it has received $8.469323 million in funding

Pluri Inc. announced that it expects to receive $8.170972 million in funding

High number of new and inexperienced directors

Pluri Receives Non-Compliance Letter from Nasdaq

Pluri Inc. Announces €7.5 Million Non-Dilutive Grant from the European Union’s Horizon Europe Program to Study PLX-PAD Cells for Osteoarthritis Treatment

Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

Pluristem Therapeutics Inc. Announces Board Changes

High number of new directors

High number of new directors

Pluristem Therapeutics Inc. and Tnuva Group Appoint Eyal Rosenthal as Chief Executive Officer of Their New Joint Venture

High number of new directors

Chairman recently bought €126k worth of stock

Pluristem Therapeutics Inc. Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19

Independent Director Isaac Braun has left the company

Insider recently sold €1.3m worth of stock

Insider recently sold €84k worth of stock

Pluristem Reports Positive Topline Phase I Results in Innovative Hematology Program, Which Is First to Study PLX-R18 in humans

New 90-day low: €4.30

Revenue in line with expectations

Pluristem Therapeutics Inc. Announces Board Appointments

Pluristem Therapeutics Inc. Enters Collaboration With Innovare R&D to Expand Its ARDS Associated With COVID-19 Program to Mexico

Pluristem Therapeutics Inc. Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study

New 90-day high: €9.75

Insider recently bought €162k worth of stock

Pluristem Therapeutics Inc. to Present Initial Results from its Phase I HCT Study

New 90-day low: €7.20

Revenue in line with expectations

Insider recently bought €158k worth of stock

Pluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease Study

New 90-day high: €9.40

Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel

Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects At Malta Conferences Foundation Online Event

Insider recently bought €269k worth of stock

Full year earnings released - €1.60 loss per share

New 90-day high - €9.30

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Pluri Inc. Samenvatting

78.2x

-1.2x

Inkomsten en omzet